Where is Cymantic located?

Cymantic is headquartered in Dublin, Ireland.

Where does Cymantic rank among its competitors?

Cymantic ranks 127th amongst 108 active competitors, of which 36 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Lucida Medical, which secured $11.5M in Mar, 2026.

Who are the top competitors of Cymantic?

Cymantic's top competitors include Scholar Rock, Lucida Medical and SamanTree Medical. Among them, Lucida Medical secured the most recent funding round in March, 2026.

Cymantic - 2026 Company Profile & Competitors

Company Details

Developer of deep learning-based devices for cancer diagnosis and treatment. These devices aim to provide real-time information to support intraprocedural decision-making. The goal is to improve patient outcomes by enhancing the accuracy of biopsies and tumour resections. The technology seeks to address the issue of undetected failures during cancer procedures. This can delay diagnosis and treatment, increasing healthcare costs and patient risks. The focus is on streamlining care delivery and improving the overall quality of cancer care.

Key Metrics

Location

Dublin, Ireland

Stage

Unfunded

Ranked

127^th among 127 competitors

Similar Companies

Lucida Medical & 103 more

View Cymantic's full profile

Cymantic has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cymantic include Scholar Rock, Lucida Medical and SamanTree Medical. Here is the list of Top 10 competitors of Cymantic, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Scholar Rock 2012, Cambridge (United States), Public	Developer of Antibody-based drugs for the treatment of primary myopathies	$103M	Fidelity Investments, Invus & 10 others	61/100
2nd	Lucida Medical 2019, Cambridge (United Kingdom), Series A	Developer of MRI-based cancer screening technology using artificial intelligence (AI)	$11.5M	prostate-cancer-research.org.uk, IW Capital ... & 23 others	59/100
3rd	SamanTree Medical 2014, Lausanne (Switzerland), Series C	Developer of digital microscopy system for high-resolution imaging of tissue	$57.5M	European Investment Bank, Panakes Partners ... & 14 others	59/100
4th	Sysmex 1968, Kobe (Japan), Public	Developer of diagnostic instruments, reagents, and related software	-	-	55/100
5th	Ionpath 2014, Menlo Park (United States), Series B	Developer of an imaging platform for tissue biopsies	$18M	Samsara BioCapital, Agile Angel & 8 others	52/100
6th	RAYDIAX 2021, Magdeburg (Germany), Series A	Developer of therapy-assist CT system for minimally invasive interventions	$8.4M	Bmp Ventures, HTGF & 4 others	52/100
7th	NeoCura 2017, Changping (China), Series A	Provider of an AI-enabled immunotherapy based tumor diagnostic platform	$38.2M	CDH, PICC Capital Investment Management & 5 others	51/100
8th	Ferronova 2016, Salisbury (Australia), Series A	Provider of magnetic probe based device of treatment of multiple cancer	$17.5M	Uniseed, Renew Pharmaceuticals & 7 others	51/100
9th	Windtree Therapeutics 1992, Philadelphia (United States), Public	Developer of therapies for oncology and cardiovascular diseases with unmet needs	$45K	VMS Asset Management, Panacea Venture & 2 others	51/100
10th	Imagion Biosystems 2016, Albuquerque (United States), Public	Developer of molecular magnetic resonance imaging technology for cancer detection	-	Marbruck Investments, HHS & 1 others	50/100
127th	Cymantic Dublin (Ireland), Unfunded	Developer of deep learning-based devices for cancer diagnosis and treatment	-	-	-